Reisa A Sperling
Overview
Explore the profile of Reisa A Sperling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
371
Citations
31952
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Honig L, Sabbagh M, van Dyck C, Sperling R, Hersch S, Matta A, et al.
Alzheimers Res Ther
. 2024 May;
16(1):105.
PMID: 38730496
Background: Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for...
32.
Schneider C, Prokopiou P, Papp K, Engels-Dominguez N, Hsieh S, Juneau T, et al.
Alzheimers Dement
. 2024 Apr;
20(6):3958-3971.
PMID: 38676563
Introduction: Animal research has shown that tau pathology in the locus coeruleus (LC) is associated with reduced norepinephrine signaling, lower projection density to the medial temporal lobe (MTL), atrophy, and...
33.
Bueicheku E, Diez I, Kim C, Becker J, Koops E, Kwong K, et al.
Nat Aging
. 2024 Apr;
4(5):625-637.
PMID: 38664576
Autopsy studies indicated that the locus coeruleus (LC) accumulates hyperphosphorylated tau before allocortical regions in Alzheimer's disease. By combining in vivo longitudinal magnetic resonance imaging measures of LC integrity, tau...
34.
Molina-Henry D, Raman R, Liu A, Langford O, Johnson K, Shum L, et al.
Alzheimers Dement
. 2024 Apr;
20(6):3827-3838.
PMID: 38629508
Introduction: In trials of amyloid-lowering drugs for Alzheimer's disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron...
35.
Grill J, Raman R, Ernstrom K, Wang S, Donohue M, Aisen P, et al.
Neurol Clin Pract
. 2024 Apr;
14(2):e200265.
PMID: 38585443
Background And Objectives: Preclinical Alzheimer disease (AD) trials simultaneously test candidate treatments and the implications of disclosing biomarker information to cognitively unimpaired individuals. Methods: The EARLY trial was a randomized,...
36.
Vascular contributions to cognitive decline: Beyond amyloid and tau in the Harvard Aging Brain Study
Shirzadi Z, Boyle R, Yau W, Coughlan G, Fu J, Properzi M, et al.
J Cereb Blood Flow Metab
. 2024 Mar;
44(8):1319-1328.
PMID: 38452039
In addition to amyloid and tau pathology, elevated systemic vascular risk, white matter injury, and reduced cerebral blood flow contribute to late-life cognitive decline. Given the strong collinearity among these...
37.
Burling J, Katz Z, Yuan Z, Munro C, Mimmack K, Ma G, et al.
Am J Geriatr Psychiatry
. 2024 Mar;
32(8):909-919.
PMID: 38443298
Objectives: We examined relationships between apathy (self and study-partner-reported) and markers of Alzheimer's disease (AD) in older adults. Design: The study utilized a well-characterized sample of participants from the Harvard...
38.
Yang H, Yau W, Carlyle B, Trombetta B, Zhang C, Shirzadi Z, et al.
Brain
. 2024 Feb;
147(6):2158-2168.
PMID: 38315899
Vascular dysfunction is increasingly recognized as an important contributor to the pathogenesis of Alzheimer's disease. Alterations in vascular endothelial growth factor (VEGF) pathways have been implicated as potential mechanisms. However,...
39.
Agarwal K, Backler W, Bayram E, Bloom L, Boeve B, Cha J, et al.
Alzheimers Dement
. 2024 Jan;
20(3):2298-2308.
PMID: 38265159
Despite its high prevalence among dementias, Lewy body dementia (LBD) remains poorly understood with a limited, albeit growing, evidence base. The public-health burden that LBD imposes is worsened by overlapping...
40.
Sexton C, Bitan G, Bowles K, Brys M, Buee L, Maina M, et al.
Alzheimers Dement
. 2024 Jan;
20(3):2240-2261.
PMID: 38170841
Introduction: The pace of innovation has accelerated in virtually every area of tau research in just the past few years. Methods: In February 2022, leading international tau experts convened to...